Literature DB >> 33458563

Cerebral Infarction in Immune Thrombotic Thrombocytopenic Purpura Is Associated with Old Age, Hypertension, Smoking, and Anti-ADAMTS13 Ig, But Not with Mortality.

Raima Memon1, Jingrui Sui1, Chen Lin2, X Long Zheng1,3.   

Abstract

Background  Neurological involvement is common in patients with immune thrombotic thrombocytopenic purpura (iTTP), but the frequency, risk factors, and outcomes of these with imaging-confirmed stroke in iTTP are not known. Methods  We selected 66 out of 109 iTTP patients with neurological signs and symptoms and reviewed their CT/MRI (computed tomography/magnetic resonance imaging) findings for the evidence of stroke and other clinical information in Alabama TTP Registry. Results  Of these, 52 (78.8%) had their CT/MRI done on admission in whom 22 (42.3%) were positive for multiple acute or chronic infarcts. The patients with image-confirmed ischemic stroke were older, and appeared to be associated with a history of hypertension and smoking. Additionally, patients with imaging-confirmed stroke showed higher plasma concentrations of anti-ADAMTS13 IgG than those without stroke. More interestingly, there was no statistically significant difference in the rate of exacerbation and 60-day mortality between those with and without stroke. Conclusion  Ischemic cerebral infarcts are common findings in brain imaging studies of patients with acute iTTP; old age, chronic hypertension, and smoking, as well as high plasma concentrations of anti-ADAMTS13 IgG may be the potential risk factors for cerebral infarction in these patients. The presence of image-confirmed ischemic stroke, however, does not predict exacerbation and 60-day mortality, although the long-term effect of such ischemic brain damage on cognitive function and quality of life remains to be determined. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).

Entities:  

Keywords:  ADAMS/ADAMTS13; autoantibodies; autoimmune diseases; cerebrovascular disease; inflammatory mediators; thrombotic thrombocytopenic purpura; von Willebrand factor

Year:  2021        PMID: 33458563      PMCID: PMC7806360          DOI: 10.1055/s-0040-1722610

Source DB:  PubMed          Journal:  TH Open        ISSN: 2512-9465


  46 in total

Review 1.  Plasma exchange in the management of thrombotic thrombocytopenic purpura.

Authors:  Gail Rock
Journal:  Vox Sang       Date:  2002-08       Impact factor: 2.144

Review 2.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

Review 3.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

4.  Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Roberto C Montoya; Bernard J Poiesz
Journal:  Blood Coagul Fibrinolysis       Date:  2012-06       Impact factor: 1.276

5.  Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident.

Authors:  Katharine A Downes; Roslyn Yomtovian; H M Tsai; Bernard Silver; Cynthia Rutherford; Ravindra Sarode
Journal:  J Clin Apher       Date:  2004       Impact factor: 2.821

6.  ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

7.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

8.  ST segment elevation myocardial infarction as a presenting feature of thrombotic thrombocytopenic purpura.

Authors:  Auras R Atreya; Sonali Arora; Senthil K Sivalingam; Gregory R Giugliano
Journal:  J Cardiovasc Dis Res       Date:  2012-04

Review 9.  Cardiac implications of thrombotic thrombocytopenic purpura.

Authors:  Szymon L Wiernek; Bo Jiang; Gregory M Gustafson; Xuming Dai
Journal:  World J Cardiol       Date:  2018-12-26

10.  Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors.

Authors:  Suella Martino; Mathieu Jamme; Christophe Deligny; Marc Busson; Pascale Loiseau; Elie Azoulay; Lionel Galicier; Frédéric Pène; François Provôt; Antoine Dossier; Samir Saheb; Agnès Veyradier; Paul Coppo
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

View more
  1 in total

Review 1.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.